ALERT: This system is being upgraded on Tuesday December 12. It will not be available
for use for several hours that day while the upgrade is in progress. Deposits to DukeSpace
will be disabled on Monday December 11, so no new items are to be added to the repository
while the upgrade is in progress. Everything should be back to normal by the end of
day, December 12.
Browsing by Author "Grabowski, HG"
Now showing items 1-20 of 34
-
A Computer Simulation Model of Pharmaceutical Innovation
(Pharmaceutical Economics, 1984) -
A Computer Simulation Model of Pharmaceutical Innovation
(Pharmaceutical Economics: Papers Presented at the 6. Arne Ryde Symposium, Helsingborg, Sweden 1982, 1984) -
An Economic Analysis of Global Policy Proposals to Prohibit Compensation of Blood Plasma Donors
(International Journal of the Economics of Business, 2016-05-03)© 2016 International Journal of the Economics of Business.Human blood plasma and its derivative therapies have been used therapeutically for more than 50 years, after first being widely used to treat injuries during World ... -
Competition between Generic and Branded Drugs
(Pharmaceutical innovation: incentives, competition, and cost-benefit analysis in international perspective, 2007-04-30)The pharmaceutical industry worldwide is a rapidly burgeoning industry contributing to growth of gross domestic product and employment. Technological change in this field has been very rapid, with many new products being ... -
Cost of innovation in the pharmaceutical industry.
(J Health Econ, 1991-07)The research and development costs of 93 randomly selected new chemical entities (NCEs) were obtained from a survey of 12 U.S.-owned pharmaceutical firms. These data were used to estimate the pre-tax average cost of new ... -
Economic Evaluation of Drug Treatment for Psychiatric Disorders: The New Clinical Trial Protocol
(Psychopharmacology: the Fourth Generation of Progress, 1995) -
Encouraging innovative treatment of neglected diseases through priority review vouchers
(Prescribing Cultures and Pharmaceutical Policy in the Asia-Pacific, 2009-09-01) -
Entry and competition in generic biologics
(Managerial and Decision Economics, 2007-06-01)Patents for several blockbuster biological products are expected to expire soon. The Food and Drug Administration is examining whether biologies can and should be treated like pharmaceuticals with regard to generics. In ... -
Estimating the Effects of Regulation on Innovation: An International Comparative Analysis of the Pharmaceutical Industry
(1978)INNOVATION in the U.S. ethical drug industry in recent years has been characterized by a number of adverse developments. In particular, there has been a sharp decline in the rate of new product introductions and the incentive ... -
FDA in the Twenty-First Century
(FDA Regulation Of Biosimilars, 2015) -
Generic competition and market exclusivity periods in pharmaceuticals
(Managerial and Decision Economics, 2007-06-01)In this paper we examine generic competition and market exclusivity periods for pharmaceuticals experiencing their initial generic entry between 1995 and 2005. We find that generic competition has increased over several ... -
Graph-Oriented Model for Research Management
(Research program effectiveness. Proceedings of the conference sponsored by the Office of Naval Research, Washington, D.C., July 27-29, 1965. Edited by M. C. Yovits [and others], etc, 1966) -
Impact of Public Policy on Drug Innovation and Pricing
(Impact of Public Policy on Drug Innovation and Pricing, 1976) -
Increasing R&D Incentives for Neglected Diseases: Lessons from the Orphan Drug Act
(International Public Goods And Transfer Of Technology Under A Globalized Intellectual Property Regime, 2005) -
Increasing R&D incentives for neglected diseases: Lessons from the Orphan Drug Act
(International Public Goods And Transfer Of Technology Under A Globalized Intellectual Property Regime, 2005)Distinguished economists, political scientists, and legal experts discuss the implications of the increasingly globalized protection of intellectual property rights for the ability of countries to provide their citizens ... -
Innovation and International Competitiveness in Pharmaceuticals
(Evolving Technology and Market Structure: Studies in Schumpeterian Economics, 1990) -
Mergers and Alliances in Pharmaceutical: Effects on Innovation and R&D Productivity
(The Economics of Corporate Governance and Mergers, 2008-01-01)This book provides an insightful view of major issues in the economics of corporate governance (CG) and mergers. It presents a systematic update on the developments in the two fields during the last decade, as well ... -
Mergers, Acquisitions, and Alliances
(The Oxford Handbook of the Economics of the Biopharmaceutical Industry, 2012-09-18)© 2012 by Oxford University Press. All rights reserved.This article considers the determinants and effects of M&As in the pharmaceutical industry, with a particular focus on innovation and R&D productivity. As is the case ... -
Pressures from the Demand Side: Changing Market Dynamics and Industrial Structure
(Consolidation and Competition in the Pharmaceutical Industry, 2001)
